A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Public ClinicalTrials.gov record NCT07059845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay. Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 3 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2 doses of MIRV with Bev, or Bev alone. In substudy 2, arms D and E, participants will receive 1 of 2 doses of MIRV with carboplatin, followed by MIRV alone. In substudy 3, arms F and G, participants will receive one of two doses of MIRV with BEV and carboplatin, followed by MIRV with BEV. Approximately 400 participants will be enrolled in the study at 100 sites around the world. Participants will receive intravenously (IV) infused MIRV with IV infused carboplatin, or IV infused Bev, or IV infused carboplatin and Bev, or IV infused Bev alone. The total study duration will be approximately 40 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Study identification
- NCT ID
- NCT07059845
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2025
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2028
- Last update posted
- Aug 20, 2026
2025 – 2029
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Health - Moores Cancer Center /ID# 277574 | La Jolla | California | 92037 | Recruiting |
| Sansum Clinic - Solvang /ID# 277712 | Solvang | California | 93463 | Active, not recruiting |
| University of Florida College of Medicine /ID# 278348 | Gainesville | Florida | 32610 | Recruiting |
| Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623 | Orlando | Florida | 32806 | Recruiting |
| Florida Cancer Specialists - North /ID# 278626 | St. Petersburg | Florida | 33705 | Recruiting |
| Florida Cancer Specialists - East /ID# 278605 | West Palm Beach | Florida | 33401 | Recruiting |
| Baptist Health Lexington /ID# 278267 | Lexington | Kentucky | 40503 | Recruiting |
| Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440 | Baton Rouge | Louisiana | 70817 | Recruiting |
| Maine Medical Center - Scarborough Campus /ID# 277205 | Scarborough | Maine | 04074 | Recruiting |
| UMass Memorial Medical Center - Belmont Street /ID# 278628 | Worcester | Massachusetts | 01605 | Recruiting |
| Karmanos Cancer Institute - Detroit /ID# 277085 | Detroit | Michigan | 48201 | Recruiting |
| Intermountain Health - Intermountain Health West End Clinic /ID# 278470 | Billings | Montana | 59106 | Recruiting |
| Md Anderson Cancer Center At Cooper /ID# 278390 | Camden | New Jersey | 08103 | Recruiting |
| SUNY Upstate Medical University - Syracuse /ID# 277245 | Syracuse | New York | 13210 | Recruiting |
| FirstHealth of the Carolinas- Speciality Center /ID# 278636 | Pinehurst | North Carolina | 28374 | Recruiting |
| Jamescare Gynecologic Oncology At Mill Run /ID# 277951 | Hilliard | Ohio | 43026 | Recruiting |
| Willamette Valley Cancer Institute and Research Center /ID# 277714 | Eugene | Oregon | 97401 | Recruiting |
| Penn Medicine University of Pennsylvania Health System /ID# 277963 | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Western Pennsylvania Gynecologic Oncology /ID# 278632 | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| Avera Cancer Institute - Sioux Falls /ID# 278627 | Sioux Falls | South Dakota | 57105 | Recruiting |
| University Of Tennessee Medical Center /ID# 278225 | Knoxville | Tennessee | 37920 | Recruiting |
| Texas Oncology - Abilene - Antilley Road /ID# 277739 | Abilene | Texas | 79606 | Recruiting |
| Texas Oncology - Fort Worth Cancer Center /ID# 277989 | Fort Worth | Texas | 76104 | Recruiting |
| Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735 | San Antonio | Texas | 78240 | Recruiting |
| Texas Oncology - The Woodlands /ID# 277926 | The Woodlands | Texas | 77380 | Recruiting |
| Texas Oncology - Northeast Texas /ID# 277737 | Tyler | Texas | 75702 | Recruiting |
| Virginia Mason Hospital and Medical Center /ID# 277259 | Seattle | Washington | 98101 | Recruiting |
| West Virginia University Hospitals /ID# 278965 | Morgantown | West Virginia | 26506 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07059845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07059845 live on ClinicalTrials.gov.